China's National Medical Products Administration approved a clinical trial for CStone Pharmaceuticals' histone deacetylase 6 selective inhibitor CS3003. The drug is intended to treat multiple myeloma.
Chinese regulators approve clinical trial of multiple myeloma drug
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.